Perspective Therapeutics (CATX) Barclays 27th Annual Global Healthcare Conference summary

Supply chain and regulatory environment

• Tariffs have minimal impact due to domestic sourcing of key precursors and isotopes, primarily from the U.S. Department of Energy.

• No observed changes in FDA engagement or delays due to potential FDA budget cuts; FDA remains supportive of innovation.

• NIH funding cuts are causing acute impacts at clinical trial sites, affecting institutional budgets and patient care.

Manufacturing and distribution strategy

• Product shelf life for Lead-212 is about 24 hours, enabling same-day or overnight distribution.

• Manufacturing sites in Iowa, New Jersey, Houston, Los Angeles, and Chicago support national distribution.

• Facilities are efficient, with capital requirements under $40 million, and use chemical separation for isotope purification.

Platform differentiation and clinical approach

• Lead-212 chosen for optimal half-life and therapeutic profile; paired with Lead-203 for precise dosimetry.

• Proprietary chelator technology enables targeted delivery and IP protection.

• Platform allows for tuning of biodistribution and pharmacokinetics, supporting rapid preclinical and clinical development.